Qiagen N.V. has announced that its NeuMoDx human  immunodeficiency virus type 1 (HIV-1), hepatitis B virus (HBV) and hepatitis C virus (HCV) quantitative assays for blood-borne virus (BBV) testing has received Central Drugs Standard Control Organization (CDSCO) approval in India. These blood-borne virus assays are the first to be registered in India with  additional NeuMoDx infectious disease assays to follow. 

The NeuMoDx HIV-1 Quant Assay is designed for the quantitation and detection of human  immunodeficiency virus type 1 (HIV-1) RNA in human plasma. It can be used as an aid in the clinical  management of HIV-1 infected patients and monitoring the effects of anti-retroviral treatment, as measured  by changes in plasma HIV-1 RNA levels, and as an aid in the diagnosis of HIV-1 infection, including acute  or primary infection. 

The NeuMoDx HBV Quant Assay is designed for the quantitation of hepatitis B virus (HBV) DNA in human  plasma and serum specimens for HBV genotypes A through H of HBV-infected individuals. It is intended to  be used as an aid for determining proper course of treatment for patients with HBV infection 

On the other hand, the NeuMoDx HCV Quant Assay is designed for the quantitation of hepatitis C virus (HCV) RNA genotypes  1 through 6 in human plasma and serum specimens from HCV antibody positive individuals. It is intended  to be used as an aid in the management of patients with HCV infections.